Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Bladder Dysfunction Reports
Published in: Current Bladder Dysfunction Reports 4/2019

01-12-2019 | Overactive Bladder | Overactive Bladder (U Lee and S Adelstein, Section Editors)

The Role of Local Hormone Replacement in Overactive Bladder

Authors: Dudley Robinson, Linda Cardozo

Published in: Current Bladder Dysfunction Reports | Issue 4/2019

Login to get access

Abstract

Purpose of Review

Overactive bladder (OAB) is a common and distressing condition which is known to increase with age and to have a significant effect on quality of life (QoL). Whilst OAB is a symptomatic diagnosis, many patients will require basic investigations prior to initiating the appropriate management. This paper will explore the prevalence and pathophysiology of OAB as well as diagnosis and management of the condition.

Recent Findings

There is increasing evidence that local oestrogen therapy may be beneficial in the management of postmenopausal women with OAB, either when used alone or as combination therapy with an antimuscarinic drug. This paper will review the postulated mechanisms of action as well as exploring the available evidence base supporting efficacy.

Summary

There is now a substantial evidence base to support the use of local vaginal oestrogen therapy in postmenopausal women with OAB either in isolation or alternatively as an adjunctive therapy when used with antimuscarinic medication. Available evidence supports an improvement in lower urinary tract symptoms as well as a significant improvement in health-related quality of life (HRQoL).
Literature
1.
Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5–26. Standardisation of lower urinary tract terminology document. PubMedCrossRef
2.
Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: results from the NOBLE program. Int Urogynaecol. J. 2001;12(3):S66.
3.
Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87(9):760–6.CrossRefPubMed
4.
Anderson KE. The overactive bladder: pharmacologic basis of drug treatment. Urology. 1997;50:74–89.CrossRef
5.
Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol. 2006;175:191–5.PubMedCrossRef
6.
Caulfield MP, Birdsall NJ. International Union of Pharmacology XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev. 1998;50:279.PubMed
7.
Braverman AS, Ruggieri MR. The M2 receptor contributes to contraction of the denervated rat urinary bladder. Am J Physiol. 1998;275:1654.
8.
Cartwright R, Panayi D, Cardozo L, Khullar V. Reliability and normal ranges for the Patient’s Perception of Intensity of Urgency Scale in asymptomatic women. BJU Int. 2010;105:832–6.PubMedCrossRef
9.
Cardozo L, Coyne KS, Versi E. Validation of the urgency perception scale. BJU Int. 2005;95:591–6.PubMedCrossRef
10.
Nixon A, Colman S, Sabounjian L, et al. A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials. JUrol. 2005;174:604–7.
11.
Jenkinson C, Coulter A, Wright L. Short Form 36 (SF-36) health survey questionnaire. Normative data for adults of working age. British Medical Journal. 1993;306:1437–40.PubMedCrossRefPubMedCentral
12.
Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. British Journal of Obstetrics and Gynaecology. 1997;104:1374–9.PubMedCrossRef
13.
Swithinbank L, Hashim H, Abrams P. The effect of fluid intake on urinary symptoms in women. J Urol. 2005 Jul;174(1):187–9.PubMedCrossRef
14.
Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med. 2009;360(5):481–90.PubMedPubMedCentralCrossRef
15.
Jeffcoate TNA, Francis WJA. Urgency incontinence in the female. American Journal of Obstetrics and Gynecology. 1966;94:604–18.PubMedCrossRef
16.
Berghmans LC, Hendricks HJ, de Bie RA, van Waalwijk van Doorn ES, Bo K, van Kerrebroeck PE. Conservative treatment of urge urinary incontinence in women: a systematic review of randomised clinical trials. British Journal of Urology International. 2000;85:254–63.CrossRef
17••.
NICE Guideline (NG123). The Management of Urinary Incontinence in Women. Department of Health. www.​nice.​org.​uk. 2019. Recent update of the National UK guidelines.
18••.
Dumoulin C, Adewuyi T, Booth J, Bradley C, Burgio K, Hagen S, Hunter K, Imamura M, Morin M, Morkved K, Thakar R, Wallace S, Williams K. Adult Conservative Management. In: Incontinence, 6th Edition. Abrams P, Cardozo L, Wagg A, Wein A, editors. IUCD ICS 1443-1628. 2017. Sixth report of the International Consultation on Incontinence.
19••.
Prasad Rai B, Cody JD, Alhasso AA, Stewart L. Anticholinergic drugs versus non drug active therapies for overactive bladder syndrome in adults. Cochrane Database of Systematic Reviews. 2012. https://​doi.​org/​10.​1002/​14651858.​CD003193.​pub4Cochrane review examining the efficacy of antimuscarinic therapy in overactive bladder.
20••.
Andersson KE, Cardozo L, Cruz F, Lee KS, Sahai A, Wein AJ. Pharmacological treatment of urinary incontinence. In Incontinence, 6th Edition. Abrams P, Cardozo L, Wagg A, editors. Wein IUCD ICS 805 - 958. 2017. Sixth report of the International Consultation on Incontinence.
21.
Hadorn DC, Baker D, Hodges JS, Hicks N. Rating the quality of evidence for clinical practice guidelines. J Clin Epidemiol. 1996;49(7):749–54.PubMedCrossRef
22.
23.
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.CrossRefPubMed
24.
Araklitis G, Thiagamoorthy G, Hunter J, Rantell A, Robinson D, Cardozo L. Anticholinergic prescription: are healthcare professionals the real burden? Int Urogynaecol J. 2017;28:1249–56.CrossRef
25.
Fox C, Smith T, Maidment I, Chan WY, Bua N, Myint PK, et al. Effect of medications with anticholinergic properties on cognitive function, delirium, physical function and mortality: a systematic review. Age Ageing. 2014;43:604–15.PubMedCrossRef
26.
Fox C, Richardson K, Maidment ID, Savva GM, Matthews FE, Smithard D, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011;59:1477–83.PubMedCrossRef
27•.
Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics ad incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175:401–7. A prospective study looking at the association of anticholinergic drug usage and the long term risk of cognitive decline.PubMedPubMedCentralCrossRef
28••.
29.
Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev. 2004;84:935–86.PubMedCrossRef
30.
Otsuka A, Shinbo H, Matsumoto R, Kurita Y, Ozono S. Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:473–81.PubMedCrossRef
31.
Sacco E, Bientinesi R, Tienforti D, Racioppi M, Gulino G, D'Agostino D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov. 2014;9:433–48.PubMedCrossRef
32.
Hicks A, McCafferty G, Riedel E, Aiyar N, Pullen M, Evans C, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther. 2007;323:202–9.PubMedCrossRef
33.
Khullar V, Amarenco G, Angulo JC, Cambronero J, Hoye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta 3 adrenoreceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase III trial. Eur Urol. 2013;63:283–95.PubMedCrossRef
34.
Chapple CR, Kaplan SA, Mitcheson D, Klecka J, Cummings J, Drogendijk T, et al. Randomised double-blind, active-controlled phase III study to assess 12 month safety and efficacy of mirabegron, a beta 3 adrenoreceptor agonist, in overactive bladder. Eur Urol. 2013;63:296–305.PubMedCrossRef
35.
Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double blind muticentre phase 3B study (BESIDE). Eur Urol. 2016;70:136–45.PubMedCrossRef
36.
Cheng CL, Li JR, Lin CH, de Groat WC. Positive association of female overactive bladder symptoms and oestrogen deprivation: a nationwide population based cohort study in Taiwan. Medicine (Baltimore). 2016;95:e4107.CrossRef
37.
Hong SK, Yang JH, Kim TB, Kim SW, Paick JS. Effects of ovariectomy and oestrogen replacement on the function and expression of Rho-kinase in rat bladder smooth muscle. BJU Int. 2006;98:1114–7.PubMedCrossRef
38.
Yoshida J, Aikawa K, Yoshimura Y, Shishido K, Yanagida T, Yamaguchi O. The effects of ovariectomy and oestrogen replacement on acetylcholine release from nerve fibres and passive stretch induced acetylcholine release in female rats. Neurourol Urodyn. 2007;26:1050–5.PubMedCrossRef
39.
Petkov GV. Central role of the BK channel in urinary bladder smooth muscle physiology and pathophysiology. Am J Physiol Requl Integr Comp Physiol. 2014;307:R571–84.CrossRef
40.
Xin W, Li N, Fernandes VS, Chen B, Rovner ES, Petkov GV. BK Channel regulation by phoshodiesterase type 1: a novel signaling pathway controlling human detrusor smooth muscle function. Am J Physiol Renal Physiol. 2016;310:F994–9.PubMedPubMedCentralCrossRef
41.
Provence A, Hristov KL, Parajuli SP, Petkov GV. Regulation of guinea pig detrusor smooth muscle excitability by 17β oestradiol: the role of the large conductance voltage and Ca2+ activated K+ channels. PLoS One. 2015;10:e0141950.PubMedPubMedCentralCrossRef
42.
Hristov KL, Parajuli SP, Provence A, Rovner ES, Petkov GV. Nongenomic modulation of the larger conductance voltage and Ca2+ activated K+ channels by oestrogen: a novel regulatory mechanism in human detrusor smooth muscle. Physiol Rep. 2017;5:e13351.PubMedPubMedCentralCrossRef
43.
Chen HY, Chen CJ, Chen WC, Wang SJ, Chen YH. A promising protein responsible for overactive bladder in ovariectomised mice. Taiwan J Obstet Gynaecol. 2017;56:196–203.CrossRef
44.
Samsicoe G, Jansson I, Mellstrom D, Svanberg A. Urinary incontinence in 75 year old women. Effects of oestriol. Acta. Obstet. Gynaecol. Scand. 1985;93:57.
45.
Cardozo LD, Rekers H, Tapp A, Barnick C, Shepherd A, Schussler B, et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. Maturitas. 1993;18:47–53.PubMedCrossRef
46.
Benness C, Wise BG, Cutner A, Cardozo LD. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int. Urogynaecol. J. 1992;3(2):281.
47.
Eriksen PS, Rasmussen H. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study. Eur. J. Obstet. Gynaecol. Reprod. Biol. 1992;44:137–44.CrossRef
48.
Cardozo L, Lose G, McClish D, Versi E. Estrogen treatment for symptoms of an overactive bladder, results of a meta analysis. Int J Urogynaecol. 2001;12(3):V.
49•.
Tseng LH, Wang AC, Chang YL, Soong YK, Lloyd LK, Ko YJ. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn. 2009;28(1):47–51. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB. PubMedCrossRef
50•.
Nelken RS, Ozel BZ, Leegant AR, Felix JC, Mishell DR. Radomised trial of oestradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause. 2011;18:962–6. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB. PubMedCrossRef
51.
Jiang F, Zhu L, Xu T, Gong MY, Huang YL, Li HF, et al. Menopause. 2016;23:451–7. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB. PubMedCrossRef
52•.
Chughtai B, Forde JC, Buck J, Asfaw T, Lee R, Te AE, et al. The concomitant use of fesoterodine and topical vaginal oestrogen in the management of overactive bladder and sexual dysfunction in post menopausal women. Post Reprod Health. 2016;22:34–40 A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of OAB.PubMedCrossRef
53•.
Serati M, Salvatore S, Uccella S, Cardozo L, Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity? Eur Urol. 2009;55(3):713–9. A small but important study examining the synergistic usage of vaginal oestrogen therapy and antimuscarinic medication in the management of detrusor overactivity. PubMedCrossRef
54••.
Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev. 2012:CD001405. A Cochrane review of the use of topical and systemic oestrogen therapy in postmenopausal women with urinary incontinence.
55••.
Weber MA, Kleijn MH, Langendam M, Limpens J, Heineman MJ, Roovers JP. Local Oestrogen for pelvic floor disorders: a systematic review. PLoS One. 2015;10(9):e0136265. A systematic review of local oestrogen therapy in the management of pelvic floor dysfunction. PubMedPubMedCentralCrossRef
Metadata
Title
The Role of Local Hormone Replacement in Overactive Bladder
Authors
Dudley Robinson
Linda Cardozo
Publication date
01-12-2019
Publisher
Springer US
Published in
Current Bladder Dysfunction Reports / Issue 4/2019
Print ISSN: 1931-7212
Electronic ISSN: 1931-7220
DOI
https://doi.org/10.1007/s11884-019-00558-z

Other articles of this Issue 4/2019

Current Bladder Dysfunction Reports 4/2019 Go to the issue

Inflammatory/Infectious Bladder Disorders (MS Mourad, Section Editor)

Central Nervous System Changes in Pelvic Inflammation/Pain Patients

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editors)

Vesicourethral Anastomotic Stenosis after Prostate Cancer Treatment

Overactive Bladder (U Lee and S Adelstein, Section Editors)

The Bladder is Not Sterile: an Update on the Urinary Microbiome

Cancer-Associated Voiding Dysfunction (S Elliott and J Pariser, Section Editors)

Radiation Cystitis: a Contemporary Review

Stress Incontinence and Prolapse (WS Reynolds, Section Editor)

Hormone Replacement for Pelvic Floor Disorders

Overactive Bladder (U Lee and S Adelstein, Section Editors)

Overactive Bladder in Diabetes Mellitus